Experienced in Sarcoidosis

Dr. Sandeep Bansal

Cardiology
217 Harrisburg Avenue, 
Lancaster, PA 
On Staff At
Accepting New Patients
Experienced in Sarcoidosis
217 Harrisburg Avenue, 
Lancaster, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Sandeep Bansal is a Cardiologist in Lancaster, Pennsylvania. Dr. Bansal is rated as an Experienced provider by MediFind in the treatment of Sarcoidosis. His top areas of expertise are Atrial Fibrillation, Arrhythmogenic Right Ventricular Cardiomyopathy, Familial Progressive Cardiac Conduction Defect, Pacemaker Implantation, and Advanced Bronchoscopy. Dr. Bansal is currently accepting new patients.

His clinical research consists of co-authoring 25 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Sarcoidosis.

Graduate Institution
Yale University
Residency
Massachusetts General Hospital/Brigham and Women’s Hospital
Specialties
Cardiology
Licenses
Internal Medicine in PA
Board Certifications
Clinical Cardiac Electrophysiology, 2012
Cardiovascular Disease, 2010
Fellowships
Massachusetts General Hospital/Brigham and Women’s Hospital
Johns Hopkins Hospital
Hospital Affiliations
Lancaster General Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Geisinger
  • HMO
  • POS
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

The Heart Group of Lancaster General Health
217 Harrisburg Avenue, Lancaster, PA 17603

Additional Areas of Focus

Dr. Bansal has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Paroxysmal Supraventricular Tachycardia (PSVT)
Mitral Valve Regurgitation
Hypertension
Sick Sinus Syndrome
Endocarditis
Giant Cell Myocarditis
Heart Murmurs
Pericarditis
Pulmonary Edema
Mitral Valve Prolapse
Atrial Septal Defect (ASD)
Fainting
Patent Foramen Ovale
Heart Failure
Pulmonary Valve Stenosis
Atherosclerosis
Cardiomyopathy
Aortic Valve Stenosis
View 8 Less Areas of Focus-

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
Enrollment Status: Completed
Publish Date: October 15, 2025
Intervention Type: Biological, Drug, Device
Study Drugs: Depemokimab, Mepolizumab, Benralizumab
Study Phase: Phase 3
Evaluating MRI Scanning in Patients With Fractured or Abandoned Endocardial Leads
Evaluating MRI Scanning in Patients With Fractured or Abandoned Endocardial Leads
Enrollment Status: Terminated
Publish Date: September 16, 2025
Intervention Type: Procedure
Study Phase: Not Applicable
Stimulation Of the Left Ventricular Endocardium for Cardiac Resynchronization Therapy in Non-Responders, Previously Untreatable and High Risk Upgrade Patients (SOLVE CRT)
Stimulation Of the Left Ventricular Endocardium for Cardiac Resynchronization Therapy in Non-Responders, Previously Untreatable and High Risk Upgrade Patients (SOLVE CRT)
Enrollment Status: Active_not_recruiting
Publish Date: July 09, 2025
Intervention Type: Device
Study Phase: Not Applicable
Zephyr Valve Registry
Zephyr Valve Registry
Enrollment Status: Active_not_recruiting
Publish Date: April 29, 2025
Intervention Type: Device
Needle-Based Confocal Laser Endomicroscopy to Aid in Lung Nodule Localization by Robotic-Assisted Navigational Bronchoscopy
Needle-Based Confocal Laser Endomicroscopy to Aid in Lung Nodule Localization by Robotic-Assisted Navigational Bronchoscopy
Enrollment Status: Completed
Publish Date: April 25, 2025
Intervention Type: Device
Study Phase: Not Applicable
Transbronchial Biopsy Assisted by Robot Guidance in the Evaluation of Tumors
Transbronchial Biopsy Assisted by Robot Guidance in the Evaluation of Tumors
Enrollment Status: Completed
Publish Date: February 28, 2025
Intervention Type: Device
A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype
A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype
Enrollment Status: Completed
Publish Date: November 29, 2024
Intervention Type: Biological
Study Drug: Depemokimab
Study Phase: Phase 3
A Sham Controlled Prospective Randomized Clinical Trial of the RejuvenAir® System for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease With Chronic Bronchitis
A Sham Controlled Prospective Randomized Clinical Trial of the RejuvenAir® System for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease With Chronic Bronchitis
Enrollment Status: Active_not_recruiting
Publish Date: June 03, 2024
Intervention Type: Device
Study Phase: Not Applicable
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
Enrollment Status: Terminated
Publish Date: November 24, 2023
Intervention Type: Drug
Study Drug: Inhaled treprostinil solution
Study Phase: Phase 3
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks (With a 48-week Safety Subset) in Subjects With Moderate to Severe COPD
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks (With a 48-week Safety Subset) in Subjects With Moderate to Severe COPD
Enrollment Status: Completed
Publish Date: November 13, 2023
Intervention Type: Drug
Study Drug: Ensifentrine
Study Phase: Phase 3
A Phase IV, 12 Week, Randomised, Double-blind, Double-dummy Study to Compare Single Inhaler Triple Therapy, Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI), With Tiotropium Monotherapy Based on Lung Function and Symptoms in Participants With Chronic Obstructive Pulmonary Disease
A Phase IV, 12 Week, Randomised, Double-blind, Double-dummy Study to Compare Single Inhaler Triple Therapy, Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI), With Tiotropium Monotherapy Based on Lung Function and Symptoms in Participants With Chronic Obstructive Pulmonary Disease
Enrollment Status: Completed
Publish Date: July 15, 2021
Intervention Type: Drug, Device
Study Phase: Phase 4
Establishment of a Registry for Patients Treated With Photodynamic Therapy (PDT)
Establishment of a Registry for Patients Treated With Photodynamic Therapy (PDT)
Enrollment Status: Terminated
Publish Date: February 24, 2020
Intervention Type: Other
A Multicenter, Prospective, Open-label, Non-randomized Single-arm Clinical Study of the Safety and Tissue Response to Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Solid Lung Tumor Prior to Surgical Resection
A Multicenter, Prospective, Open-label, Non-randomized Single-arm Clinical Study of the Safety and Tissue Response to Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Solid Lung Tumor Prior to Surgical Resection
Enrollment Status: Completed
Publish Date: January 13, 2020
Intervention Type: Device, Drug
Study Phase: Phase 1
View 12 Less Clinical Trials

25 Total Publications

Correction: Strength of motivation and academic performance of medical students: a longitudinal study.
Correction: Strength of motivation and academic performance of medical students: a longitudinal study.
Journal: BMC medical education
Published: August 28, 2025
Similar Doctors
Elite in Sarcoidosis
Dr. Nisha A. Gilotra
Advanced Heart Failure and Transplant Cardiology | Cardiology
Elite in Sarcoidosis
Dr. Nisha A. Gilotra
Advanced Heart Failure and Transplant Cardiology | Cardiology

Johns Hopkins University

600 N Wolf St, 
Baltimore, MD 
 (53.9 miles away)
410-955-5000
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients

Nisha Gilotra is an Advanced Heart Failure and Transplant Cardiologist and a Cardiologist in Baltimore, Maryland. Dr. Gilotra is rated as an Elite provider by MediFind in the treatment of Sarcoidosis. Her top areas of expertise are Sarcoidosis, Myocarditis, Cardiomyopathy, Heart Transplant, and Endoscopy. Dr. Gilotra is currently accepting new patients.

Elite in Sarcoidosis
Dr. Jonathan Chrispin
Cardiac Electrophysiology | Cardiology
Elite in Sarcoidosis
Dr. Jonathan Chrispin
Cardiac Electrophysiology | Cardiology

Johns Hopkins University

4924 Campbell Blvd, Suite 110, 
Baltimore, MD 
 (47.0 miles away)
443-442-2000
Experience:
16+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jonathan Chrispin is a Cardiac Electrophysiologist and a Cardiologist in Baltimore, Maryland. Dr. Chrispin has been practicing medicine for over 16 years and is rated as an Elite provider by MediFind in the treatment of Sarcoidosis. His top areas of expertise are Ventricular Tachycardia, Arrhythmias, Sarcoidosis, Cardiac Ablation, and Pacemaker Implantation. Dr. Chrispin is currently accepting new patients.

Elite in Sarcoidosis
Dr. Paco E. Bravo
Nuclear Medicine | Cardiology
Elite in Sarcoidosis
Dr. Paco E. Bravo
Nuclear Medicine | Cardiology

University Of Penn-Medical Group

3400 Spruce St, 
Philadelphia, PA 
 (59.5 miles away)
Languages Spoken:
English
See accepted insurances

Paco Bravo is a Nuclear Medicine specialist and a Cardiologist in Philadelphia, Pennsylvania. Dr. Bravo is rated as a Distinguished provider by MediFind in the treatment of Sarcoidosis. His top areas of expertise are Sarcoidosis, Cardiomyopathy, Cardiac Amyloidosis, Hypertrophic Cardiomyopathy (HCM), and Heart Transplant.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bansal's expertise for a condition
ConditionClose
    View All 18 Distinguished Conditions
    View All 10 Advanced Conditions
    View All 43 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile